French Tech Funding: September 2024
Related
French Tech Funding Wire September 12: Mistral AI, Cailabs, Heetch & More!
Between September 8 and September 12, a total of 15 companies raised €2.04B, including: Scintil Photonics, NeoFarm, SafeHeal, Dianosic, Nucleon Security, Nepsis Energy, Gobano Robotics, Nona, Manitty, My Auto Specialist, NRGYS, and Zylio.
French Tech Funding Wire September 5: Zefir, Koolboks, ArcaScience & More!
Between July 21 and September 5, a total of 19 companies raised €65.495M, including: Weekera, Alpic, Byome Labs, Flagcat, VitaDX, Rewayz, NeoEarth, Santafoo, Mocli, Molecular Simulation For All (MS4ALL), MagicPost, ComicBot, Stockline, Suzaku, Addvocate.ai, FLUDIS, and Kriptown.
French Tech Funding Wire July 25: MagREEsource, Elum Energy, Praysbee & More!
Between July 21 and July 25, a total of 10 companies raised €34.285 million, including: Greenphage, Austral Dx, OnParty, Aircap, DareWin Evolution, Easy Cash, and InBrain Pharma.
French Tech Funding Wire July 18: Stellaria, Spiko, One Biosciences & More!
Between July 14 and July 18, a total of 6 companies raised €68.7 million, including: Dreampath Diagnostics, Dillico, and Retab.
Latest
French Tech Funding Wire September 12: Mistral AI, Cailabs, Heetch & More!
Between September 8 and September 12, a total of 15 companies raised €2.04B, including: Scintil Photonics, NeoFarm, SafeHeal, Dianosic, Nucleon Security, Nepsis Energy, Gobano Robotics, Nona, Manitty, My Auto Specialist, NRGYS, and Zylio.
🇫🇷 French Tech Wire: Sugar, Silicon, Serious Cash, and Slowdowns
This week: Mistral hits decacorn mode, Kyron.bio takes on glyco chaos to make safer biologics, French Tech faces headwinds, Scintil Photonics scores €50M to scale its laser chips, and Quadrille raises €500M to back bold tech bets.
French Start-ups Navigate Turbulence as Growth Slows Despite Resilient Job Creation
French start-ups navigate choppy waters as VC funding plummets 24% while employment surges 11.5%. The 2025 Barometer from France Digitale and EY reveals an ecosystem transitioning from growth-at-all-costs to sustainable profitability amid mounting political and economic headwinds.
Inside Kyron.bio’s Bold Bet to Rewrite the Rules of Antibody Drug Design
For all the buzz around antibody therapies, one overlooked culprit keeps holding them back: sugars. Paris-based Kyron.bio is tackling the hidden complexity of glycosylation — the way sugars attach to therapeutic proteins — with a platform that promises safer, longer-lasting drugs.